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Abstract
Background: In the Zurich Primary HIV infection study (ZPHI), minority drug-resistant HIV-1 variants were detected in some
acutely HIV-1-infected patients prior to initiation of early antiretroviral therapy (ART). Here, we investigated the
reappearance of minority K103N and M184V HIV-1 variants in these patients who interrupted efficient early ART after 8–27
months according to the study protocol. These mutations are key mutations conferring drug resistance to reverse
transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations.
Methodology/Principal Findings: Early ART was offered to acutely HIV-1-infected patients enrolled in the longitudinal
prospective ZPHI study. Six patients harboring and eleven patients not harboring drug-resistant viruses at low frequencies
prior to ART were included in this substudy. Minority K103N and M184V HIV-1 variants were quantified in longitudinal
plasma samples after treatment interruption by allele-specific real-time PCR. All 17 patients were infected with HIV-1
subtype B between 04/2003 and 09/2005 and received LPV/r+AZT+3TC during primary HIV-1 infection (PHI). Minority K103N
HIV-1 variants reappeared after cessation of ART in two of four patients harboring this variant during PHI and even persisted
in one of those patients at frequencies similar to the frequency observed prior to ART (,1%). The K103N mutation did not
appear during treatment interruption in any other patient. Minority M184V HIV-1 variants were detected in two patients
after ART interruption, one harboring and one not harboring these variants prior to ART.
Conclusion: Minority K103N HIV-1 variants, present in acutely HIV-1 infected patients prior to early ART, can reappear and
persist after interruption of suppressive ART containing two nucleoside/nucleotide analogue reverse transcriptase inhibitors
and a ritonavir-boosted protease inhibitor.
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Introduction
Antiretroviral therapy (ART) inhibits human immunodeficiency
virus type 1 (HIV-1) in most treated HIV-1-infected patients [1],
but eradication of the virus is currently not possible [2,3,4].
Virological failure is not uncommon due to the development of
drug-resistant viruses [5]. These viruses can be transmitted and
can cause therapy failure in treatment-naı ¨ve patients [6,7]. It is
therefore recommended to perform drug resistance testing by
population sequencing before initiating ART [8,9]. It is currently
debated whether more sensitive techniques should be routinely
applied to quantify minority drug-resistant HIV-1 variants, which
remain undetected using population sequencing [10,11]. The
impact of pre-existing minority drug-resistant HIV-1 variants on
treatment outcome was examined in numerous studies, however,
there are still remaining open questions which drug resistance
mutation is at which frequency, in which context, and at what
point clinically relevant (reviewed in [12,13,14]).
The prevalence of minority drug-resistant HIV-1 variants in
HIV-1 infected, treatment-naı ¨ve patients was measured in most
studies at one time point closely before initiation of first-line ART.
So far, kinetics of these virus populations in individual patients
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21734were examined exclusively in the context of ART. We have
reported that minority drug-resistant HIV-1 variants can be
rapidly selected in periods of inefficient ART [15,16,17].
Conversion to drug-sensitive viruses was found in patients
interrupting treatment after virological failure, but minority
drug-resistant HIV-1 variants may persist in these patients [18].
Furthermore, minority drug-resistant HIV-1 variants can emerge
in patients undergoing multiple structured treatment interruption
and can persist in off-ART periods [19].
Longitudinal analyses of natural fluctuations of minority drug-
resistant HIV-1 variants have not been performed so far. Besides
the evolutionary question about the stability of these variants
within the virus population longitudinal analyses might also be of
clinical importance. All studies on minority drug-resistant HIV-1
variants and their potential impact on ART have been performed
retrospectively. Furthermore, most of the studies quantified
minority drug-resistant HIV-1 variants in samples of the exact
day or very shortly before initiation of ART. In practice or in
prospective studies this is not an option. Thus, longitudinal
investigations of fluctuations of minority drug-resistant HIV-1
variants in the absence of drug pressure will be useful to determine
the clinical value of a certain minority drug-resistant HIV-1
variant at a certain time point. We have detected minority drug-
resistant HIV-1 variants prior to initiation of early ART in acutely
HIV-1 infected patients participating in the Zurich Primary HIV-
1 Cohort (ZPHI) [20]. Here, we studied the reappearance and fate
of these variants in patients who interrupted efficient ART. The
K103N and M184V mutations were chosen, because they are
commonly transmitted drug resistance mutations [6,7].
Methods
The protocol for this trial is available as supporting information;
see Protocol S1.
Ethics statement
The study protocol was approved by the Ethics committee of
the University Hospital of Zurich.
Study design and participants
The ZPHI study is an observational, open label, non-
randomized, single center study (www.clinicaltrials.gov;
ID:NCT00537966). During the course of this study, no deviations
from the Trial Protocol occurred. Acute and recent HIV-1
infection is defined as described previously [20,21]. Minority drug-
resistant HIV-1 variants were measured in longitudinal samples of
17 patients during treatment interruption using allele-specific real-
time PCR (AS-PCR). HIV-1 quantification, resistance testing, and
AS-PCR for detection and quantification of minority drug-
resistant HIV-1 variants harboring K103N and/or M184V
mutations were performed as described previously [20]. Details
of set-up of AS-PCR assays and data analysis are described
elsewhere [19,20]. Written informed consent was obtained from
each patient prior to inclusion.
Treatment interruption is offered to patients to investigate the
possible benefit of early ART to lower the viral set point and to
gain more ART-free years. The necessity of life-long treatment,
side effects, toxicity, and cost are considerable, thus, alternative
strategies should be investigated.
Results
Minority K103N and/or M184V HIV-1 variants were
previously detected at the earliest available time point during
acute or recent HIV-1 infection and before initiation of ART in 15
of 109 patients included in the ZPHI between March 2002 and
December 2007 [20]. Six of these 15 patients were eligible for the
current study where reappearance of minority HIV-1 variants was
studied after intended interruption of suppressive ART (,40 HIV-
1 RNA copies/ml plasma).
Nine patients were not eligible due to the following reasons: No
start of ART during acute infection (n=2), no treatment
interruption (n=5), and lost to follow-up (n=2). Thus, six patients
with and 11 patients without minority K103N and/or M184V
HIV-1 variants prior to early ART were studied. The last-men-
tioned group of patients included all patients of the ZPHI who did
not harbor minority drug-resistant HIV-1 variants at baseline,
started early ART, interrupted treatment, had longitudinal plasma
samples available with viral loads above 1,000 HIV-1 RNA
copies/ml plasma, and were acutely HIV-1 infected within the
same years the six patients with minority drug-resistant HIV-1
variants have acquired HIV-1 infection. These mutations are
associated with resistance against non nucleos(t)ide analogue
reverse transcriptase inhibitors (NNRTIs) and some NRTIs,
respectively [22]. At baseline, the M184V mutation was detected
in three and the K103N mutation in four patients at low
frequencies; patient 115 harbored both variants (figure 1; table 1)
[20]. All except one patient were acutely HIV-1 infected as
defined by detailed criteria [21]. Patients 185 was recently infected
with HIV-1, i.e., referred to our center more than 90 days after the
estimated time point of infection, however, acute HIV-1 infection
was documented (table 1). Drug resistance mutations defined as
recommended by the International AIDS Society–USA Drug
Resistance Mutations Group and the surveillance drug resistance
mutations list [8,23] were not detected by population sequencing
in any patient. All patients were men who have sex with men and
infected with HIV-1 subtype B between 2003 and 2005. All
patients started early ART with zidovudine, lamivudine, and
ritonavir-boosted lopinavir. ART was changed in nine patients
due to gastrointestinal side effects, anemia, or simplification to
once daily regimens (figure 1).
Baseline characteristics were similar between patients with and
without minority K103N and/or M184V HIV-1 variants prior to
early ART in terms of viral load at baseline (median [range] HIV-
1 RNA copies/ml plasma: 5.0610
4 [3.6610
3–3.6610
6] vs.
1.6610
5 [4.6610
3–3.3610
7]), time on ART before interruption
(median [range] months: 13.7 [8.1–21.8] vs. 17.5 [10.4–26.6]),
and duration of viral load ,40 during ART (median [range]
months: 7.3 [2.3–17.8] vs. 12.3 [5.3–18.9]).
In total, 43 and 45 longitudinal samples after treatment
interruption were measured by AS-PCR for the mutations
K103N and M184V in patients with and without these variants
at low frequencies prior to early ART, respectively. The M184V
mutation was detected three times in two patients (figure 1): In
patient 162, this variant was present at baseline and reappeared
once in the last of eight samples during treatment interruption. In
patient 141, the M184V mutation was not present prior to early
ART, but appeared in 2/5 samples after treatment interruption.
The K103N mutation was detected during treatment interrup-
tion in two patients harboring this mutation at low frequencies
prior to early ART (figure 1). In patient 174, the K103N mutation
reappeared in one of five time points. In patient 123, the K103N
mutation reappeared 2.2 months after treatment interruption and
fluctuated between 0.06 and 0.52% within the following 15
months in the absence of ART. During this time, the K103N
mutation was once not detectable (individually calculated
detection limit based on the viral load for this time point:
0.03%). This mutation disappeared and was not detectable in the
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first two time points after treatment interruption were also
negative for the K103N mutation, however, the individually
calculated detection limits were higher for these samples compared
with the following time points due to lower viral loads (0.36% and
0.09%, respectively). The K103N mutation was neither detected
during treatment interruption in the other two patients harboring
this variant nor in the 13 patients not harboring minority K103N
HIV-1 variants during primary HIV-1 infection. Reinitiation of
ART was efficient to suppress viremia below detectable limits
Figure 1. Kinetics of minority K103N and M184V HIV-1 variants in patients receiving early ART and undergoing intended treatment
interruption. Plasma viral load was measured using the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test (black and green circles, the latter represent the
time points that were used for the quantification of minority drug-resistant HIV-1 variants). The limit of 40 HIV-1 RNA copies/ml plasma is shown in
dashed lines. Periods of ART are depicted in grey shaded areas; the durations of specific drugs in the early ART regimens are indicated by differently
coloured lines. In addition, the initial ART regimen after reintroduction of ART is depicted. Minority K103N (blue triangles) and M184V (red diamonds)
HIV-1 variants were quantified by AS-PCR; percentages are given and were used to calculate the absolute amounts of these variants based on the
viral load. Percent values below the assays discriminatory abilities (0.2% for M184V and 0.01% for K103N) or the individually calculated detection
limits based on the viral load are shown by less-than signs. ART, antiretroviral therapy; AZT, zidovudine; 3TC, lamivudine; LPV, lopinavir; /r, ritonavir-
boosted; EFV, efavirenz; TDF, tenofovir; ddI, didanosine; ATV, atazanavir; FTC, emtricitabine.
doi:10.1371/journal.pone.0021734.g001
Table 1. Baseline characteristics of patients with primary HIV-1 infection.
AS-PCR
Patient ID Sex
Route of
infection
HIV-1
subtype
Year of
primary
HIV-1
infection
Estimated
time point
of infection
(weeks)
HIV-1 RNA
copies/ml
plasma
K103N
mean±SD
(%)
M184V
mean±SD
(%)
Drug
resistance
mutations
by GRT
1
st line
treatment
Patients harboring minority drug-resistant HIV-1 variants prior to early ART
108 M MSM B 2003 6.0 3,560 ,d.l. 1.060.1 none LPV/r, AZT,
3TC
115 M MSM B 2003 5.0 6,040 0.9160.24 1.060.0 none LPV/r, AZT,
3TC
123 M MSM B 2003 4.6 3,620,000 0.1860.02 ,d.l. none LPV/r, AZT,
3TC
162 M MSM B 2005 8.0 51,100 ,d.l. 0.460.0 none LPV/r, AZT,
3TC
172 M MSM B 2005 5.9 47,900 1.2560.13 ,d.l. none LPV/r, AZT,
3TC
177 M MSM B 2005 4.4 2,220,000 3.7660.79 ,d.l. none LPV/r, AZT,
3TC
Patients not harboring minority drug-resistant HIV-1 variants prior to early ART
114 M MSM B 2003 5.7 4,610 ,d.l. ,d.l. none LPV/r, AZT,
3TC
120 M MSM B 2003 10.1 27,800 ,d.l. ,d.l. none LPV/r, AZT,
3TC
122 M MSM B 2003 7.9 2,610,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
141 M MSM B 2004 5.0 495,500 ,d.l. ,d.l. none LPV/r, AZT,
3TC
145 M MSM B 2004 5.4 157,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
152 M MSM B 2004 11.7 114,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
159 M MSM B 2004 6.9 132,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
165 M MSM B 2005 2.1 22,200,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
169 M MSM B 2005 1.7 33,150,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
180 M MSM B 2005 3.6 6,050,000 ,d.l. ,d.l. none LPV/r, AZT,
3TC
185 M MSM B 2005 18.4 14,400 ,d.l. ,d.l. none LPV/r, AZT,
3TC
Abbreviations: AS-PCR, allele-specific real-time PCR; ,d.l., below detection limit; GRT, genotypic resistance testing by population sequencing; M, male; MSM, men
who have sex with men; LPV/r, lopinavir (boosted with ritonavir); AZT, zidovudine; 3TC, lamivudine.
doi:10.1371/journal.pone.0021734.t001
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independent of the detection of minority K103N and/or
M184V HIV-1 variants during treatment interruption (figure 1).
Discussion
Reappearance and fluctuations of minority K103N and/or
M184V HIV-1 variants was studied in patients initiating early
ART during primary HIV-1 infection and undergoing intended
treatment interruption of suppressive ART without any evidence
for virological failure. Some patients harbored these minority
drug-resistant HIV-1 variants prior to early ART, others did not.
Different patterns could be observed for these mutants during
treatment interruption: The M184V mutation was occasionally
detected in two patients independent of its presence prior to early
ART, which reflects probably sporadic and temporary appearance
of this drug-resistant variant. On the other hand, the K103N
mutation reappeared in two patients both harboring this minority
variant prior to early ART. In one patient, minority K103N HIV-
1 variants reappeared shortly after treatment interruption and
persisted for more than 1.2 years in the absence of any selective
pressure. Drug-related selection of K103N viruses is unlikely. One
patient did never receive an NNRTI. The other patient only
temporarily received efavirenz from months two to four, more
than 1.5 years before treatment interruption. At month two, viral
load was almost fully suppressed. We and others have shown that
the selection of minority drug-resistant HIV-1 variants during the
initial months of ART is unlikely when viremia rapidly decays
[16,20,24]. Furthermore, the K103N mutation did not appear in
any other of the five patients who switched from a ritonavir-
boosted PI to efavirenz.
If selection was the cause for the appearance of drug-resistant
variants after treatment interruption, it would have been
anticipated that the M184V mutation rather than the K103N
mutation is predominantly selected, because all patients received
lamivudine, which can rapidly select M184V viruses [22].
However, selection of the M184V mutation during continuously
fully suppressive ART in our patients is very unlikely. On the
contrary, the random and seldom appearance of the M184V
mutation in these patients suggests that viral replication is very low
or most likely even completely inhibited during ART
[25,26,27,28,29]. Differences in viral fitness could explain our
observations. The presence of the M184V mutation alleviates virus
fitness (reviewed in [30]) and these viruses are rapidly replaced by
M184 wild-type viruses in the absence of selective pressure [31],
thus, transient emergence, i.e., appearance and rapid disappear-
ance, of HIV-1 variants with reduced viral fitness is probable
during the time period of treatment interruption. On the contrary,
the K103N mutation is not associated with a major impact on viral
fitness [32,33]. The reappearance and persistence of drug-resistant
viruses without reduced replication capacities are likely after
interruption of ART.
One limitation of our study is the small number of patients. We
compensated this by testing many time points during treatment
interruption. Thus, sporadic appearance of minority M184V
HIV-1 variants could be demonstrated. This is in line with
previous theoretical predictions [34]. K103N viruses were able to
reappear and persist. That the K103N mutation also sporadically
appears can not be excluded, however, this probably occurs less
frequently compared to the M184V mutation. Furthermore, the
discriminatory ability of the K103N AS-PCR assay is 20-fold more
sensitive than the M184V AS-PCR, therefore, sporadic appear-
ance of K103N viruses would have been more easily detectable,
which was not observed.
Transmitted or once selected drug-resistant variants may persist
as major virus population or as minority variants independent of
the selective pressure by ART, which implies a threat to future
antiretroviral regimens (reviewed in [35]). The prevalence of
minority drug-resistant HIV-1 variants in treatment-naı ¨ve patients
may reflect their transmission as major virus population and
subsequent decay due to impaired viral fitness, their transmission
and persistence as minority variant, or their sporadic appearance
[34]. In some patients, the presence of minority drug-resistant
HIV-1 variants can lead to rapid selection of these viruses and
immediate therapy failure [17,36]. An association between
virological failure after temporary suppression of virus replication
and the presence of minority drug-resistant HIV-1 variants has
also been shown [37,38,39,40,41]. In contrast, other studies did
not find such an association [20,38,40,42,43,44,45]. Because of
such conflicting results and the complexity to correlate resistance
data with clinical endpoints, clinical decision trees do not yet
consider minority drug-resistant HIV-1 variants [8,9]. However,
certain minority drug-resistant HIV-1 variants may have an
impact on ART and therefore it is important to study fluctuations
of these populations in the absence of selective pressure.
In summary, we observed that the K103N mutation can
reappear and persist at low frequencies in the absence of selective
pressure after treatment interruption when it was already present
as minority drug-resistant HIV-1 variant during primary HIV-1
infection. The M184V mutation does rather show sporadic
appearance. Longitudinal studies of the kinetics of minority
drug-resistant HIV-1 variants will provide further insights in the
persistence and fluctuations of these viruses and will lead to better
understanding of the clinical relevance of minority drug-resistant
HIV-1 variants.
Supporting Information
Protocol S1 Study protocol: INFZ-ZPHI-01.01 ‘‘Characteriza-
tion of acute and recent HIV-1 infections in Zurich: a long-term
observational study.’’
(PDF)
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